Hospital procurement teams and interventional program directors evaluating a venous thrombectomy catheter manufacturer face a distinct set of questions compared with clinicians selecting a device for an individual patient. Regulatory compliance, manufacturing standards, portfolio breadth, and clinical support all factor into a sourcing decision that will affect a program's capability across many future cases. This guide outlines the key evaluation areas.
Regulatory Standing as a Starting Point
Any manufacturer supplying thrombectomy catheters into European or comparable markets should hold current CE marking under EU MDR 2017/745, reflecting conformity with the applicable regulatory framework for medical devices. Manufacturing should also be certified to ISO 13485, the international quality management standard specific to medical devices. These certifications are a baseline expectation rather than a differentiator, but confirming current status is a necessary first step in any procurement evaluation. Availability and specific indications vary by country, and buyers should always confirm current regulatory status and the Instructions for Use (IFU) for any device under consideration.
Manufacturing Scale and Quality Systems
Beyond baseline certification, procurement teams often look at a manufacturer's overall scale and track record, including how many markets the company exports to and how long its quality systems have been operating under current standards. A manufacturer with an established international presence and a documented patent portfolio may offer additional confidence regarding manufacturing consistency and ongoing product development investment.
Portfolio Depth Within the Thrombectomy Category
Because DVT presentations vary widely — from fresh, distal clot to extensive, chronic iliofemoral occlusion — a manufacturer offering multiple device types within its thrombectomy line, such as rotational, aspiration, and pharmacomechanical options, may allow a program to match device selection more precisely to clinical need without switching suppliers for different case types. Reviewing how a manufacturer's portfolio spans these categories is a useful part of the evaluation process.
INVAMED's Thrombectomy Portfolio
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Clinical Support and Training Considerations
Procurement decisions for interventional devices typically extend beyond the physical product to include manufacturer-provided training, case support, and responsiveness to technical questions from the clinical team. Programs adopting a new thrombectomy platform often value manufacturers who can provide adequate onboarding support during the initial period of clinical use.
Weighing Cost Against Capability
As with any capital and disposable device procurement, cost considerations must be balanced against clinical capability, portfolio breadth, and support quality. A lower unit cost device that does not adequately address the range of clot presentations a program encounters may ultimately be less efficient than a more comprehensive, appropriately supported platform.